NCT03493230View on ClinicalTrials.gov

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients with Metastatic Malignant Melanoma Treated with Targeted Therapies or Immunotherapy ( MALT )

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

November 8, 2022

Study Completion Date

November 8, 2022

Conditions
Malignant Melanoma Stage IVMalignant Melanoma Stage III
Interventions
BIOLOGICAL

quantification of BRAF and NRAS mutation

Quantification of cell-free BRAF and NRAS mutations with digital PCR

Trial Locations (1)

06000

nice University hospital, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT03493230 - Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients with Metastatic Malignant Melanoma Treated with Targeted Therapies or Immunotherapy ( MALT ) | Biotech Hunter | Biotech Hunter